Table 3 Prescriptions during the follow-up period in the overall myasthenia gravis population (N = 1149)
From: A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis
Treatmenta | No. of patients (%) | Median No. of prescriptions per patient (interquartile range) |
|---|---|---|
Pyridostigmine | 808 (70.3) | 13 (5–34.5) |
Prednisolone | 708 (61.6) | 15.5 (5–37.5) |
Azathioprine | 286 (24.9) | 29 (7–66) |
Mycophenolate mofetil | 40 (3.5) | 20.5 (11–52) |
Methotrexate | 47 (4.1) | 16 (6–52) |
Ciclosporin | 2 (0.2) | 26 (12–40) |
Tacrolimus | 3 (0.3) | 2 (1–814) |
Cyclophosphamide | 1 (0.1) | 3 (3–3) |
Plasmapheresis | 24 (2.1) | 1 (1–1) |
Intravenous immunoglobulin | 110 (9.6) | 1 (1–2) |